Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026)
Climb Bio's (CLYM) quarterly Income from Continuing Operations came in at 46053000.0 in Q1 2026, down 116.57% YoY from 277978156.4 in Q1 2025, and down 57.73% on a QoQ basis from 29197000.0 in Q4 2025.
Powered by 
Analysis
Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Income from Continuing Operations data on file, last reported at 46053000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 116.57% year-over-year to 46053000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98251000.0 (down 0.81% YoY) and the FY2025 annual result came in at 71287000.0, up 30.37% from the prior year.
- Income from Continuing Operations eased to 46053000.0 in Q1 2026, from 29197000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2737000.0 in Q1 2024 to a low of 57675000.0 in Q2 2024.
- A 5-year average of 19687588.24 and a median of 14493000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 89.04% — and 2025, when it plunged 676.95%.
- Tracing CLYM's Income from Continuing Operations over 5 years: stood at 14493000.0 in 2022, then sank by 69.94% to 24629000.0 in 2023, then jumped by 64.92% to 8640000.0 in 2024, then plunged by 237.93% to 29197000.0 in 2025, then plunged by 57.73% to 46053000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 46053000.0 (Q1 2026), 29197000.0 (Q4 2025), and 14461000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Climb Bio | 1.17 Bn | 1.17 Bn | - | -13.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.50 Mn |
| Mar 31, 2026 | -13.70 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Jun 30, 2025 | -8.50 Mn |
| Mar 31, 2025 | -20.73 Mn |
| Dec 31, 2024 | -8.39 Mn |
| Sep 30, 2024 | -8.95 Mn |
| Jun 30, 2024 | -54.89 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -3.77 Mn |
| Sep 30, 2023 | -3.74 Mn |
| Jun 30, 2023 | -5.60 Mn |
| Mar 31, 2023 | -22.54 Mn |
| Dec 31, 2022 | -8.79 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -13.55 Mn |
| Mar 31, 2022 | -13.13 Mn |
| Dec 31, 2021 | -10.70 Mn |
| Sep 30, 2021 | -9.38 Mn |